Prothena Corporation plc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 76.15. In total, the insiders bought 1 295 000 and sold 174 000 PRTA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
76.15
Buy 1 295 000 Shares
Sell 174 000 Shares

Historical Insider Trades

Date Type Action Person Amount
May 15, 2024 Stock Option (Right to Buy) Buy Welch Daniel G 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Selkoe Dennis J. 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Kim Helen Susan 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Ekman Lars 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Dunn William H. Jr. 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Cooke Shane 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Collier Richard T 15 000
May 15, 2024 Stock Option (Right to Buy) Buy Cobb Paula K 15 000
Mar 01, 2024 Stock Option (Right to Buy) Buy Ford David A 85 000
Mar 01, 2024 Buy Ford David A 0
Feb 27, 2024 Stock Option (Right to Buy) Buy Zago Wagner M. 85 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Walker Karin L 54 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Smith Brandon S. 85 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Nguyen Tran 85 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Malecek Michael J 85 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Kinney Gene G. 307 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Karp Carol D. 85 000
Feb 27, 2024 Stock Option (Right to Buy) Buy Garren Hideki 85 000
Feb 21, 2024 Stock Option (Right to Buy) Buy Welch Daniel G 132 000
Feb 21, 2024 Buy Welch Daniel G 0
Jan 24, 2024 Stock Option (Right to Buy) Sell Walker Karin L 5 000
Jan 24, 2024 Ordinary Shares, par value $0.01 per share Buy Walker Karin L 5 000
Jan 24, 2024 Ordinary Shares, par value $0.01 per share Sell Walker Karin L 5 000
Dec 20, 2023 Stock Option (Right to Buy) Sell Walker Karin L 5 000
Dec 20, 2023 Ordinary Shares, par value $0.01 per share Buy Walker Karin L 5 000
Click to get the best stock tips daily for free!

About Prothena Corporation plc

Prothena  plc Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease... PRTA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT